Achieve Life Sciences (ACHV) Gains from Investment Securities (2012 - 2026)
Achieve Life Sciences' (ACHV) quarterly Gains from Investment Securities came in at -$285000.0 in Q1 2026, down 413.19% YoY from $91000.0 in Q1 2025, and down 350.0% on a QoQ basis from $114000.0 in Q4 2025.
Powered by 
Analysis
Achieve Life Sciences (ACHV) Gains from Investment Securities (2012 - 2026) Analysis & Trends
Achieve Life Sciences (ACHV) has 9 years of Gains from Investment Securities data on file, last reported at -$285000.0 in Q1 2026.
- Quarterly Gains from Investment Securities fell 413.19% year-over-year to -$285000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32000.0 (down 95.15% YoY) and the FY2025 annual result came in at $408000.0, down 34.3% from the prior year.
- Gains from Investment Securities slipped to -$285000.0 in Q1 2026, from $114000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $450000.0 in Q4 2024 to a low of -$285000.0 in Q1 2026.
- A 3-year average of $82666.7 and a median of $91000.0 in 2025 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2025 — Gains from Investment Securities jumped 75.0% — and 2026, when it sank 413.19%.
- Tracing ACHV's Gains from Investment Securities over 3 years: stood at $450000.0 in 2024, then sank by 74.67% to $114000.0 in 2025, then plunged by 350.0% to -$285000.0 in 2026.
- The last three Gains from Investment Securities figures came in at -$285000.0 (Q1 2026), $114000.0 (Q4 2025), and $106000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Achieve Life Sciences | 369.90 Mn | 369.90 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 48.53 Mn |
| Mar 31, 2026 | -285,000.00 |
| Dec 31, 2025 | 114,000.00 |
| Sep 30, 2025 | 106,000.00 |
| Jun 30, 2025 | 97,000.00 |
| Mar 31, 2025 | 91,000.00 |
| Dec 31, 2024 | 450,000.00 |
| Sep 30, 2024 | 62,000.00 |
| Jun 30, 2024 | 57,000.00 |
| Mar 31, 2024 | 52,000.00 |
| Dec 31, 2017 | -39,000.00 |
| Sep 30, 2017 | -111,000.00 |
| Jun 30, 2017 | -66,000.00 |
| Mar 31, 2017 | -52,000.00 |
| Dec 31, 2016 | -118,000.00 |
| Sep 30, 2016 | -621,000.00 |
| Jun 30, 2016 | 533,000.00 |
| Mar 31, 2016 | -667,000.00 |
| Dec 31, 2015 | -1.73 Mn |
| Sep 30, 2015 | -131,000.00 |